Samsung Biologics announced on the 28th that it has signed a large-scale contract manufacturing organization (CMO) agreement worth approximately 737.3 billion won with a U.S.-based pharmaceutical company. This marks the second contract award of the year, achieving about 52% of last year's total annual order amount.
According to the announcement, the size of this contract corresponds to 16.2% of last year's consolidated revenue (4.5473 trillion won). The contract period is a total of 6 years and 8 months from today until Dec. 31, 2031. The identity of the contracting party is scheduled to be disclosed after Dec. 31, 2031, for the sake of confidentiality.
Samsung Biologics' cumulative contract amount for this year has reached a total of 2.812 trillion won. The company has secured 17 of the top 20 global pharmaceutical companies as clients. Last year's annual contract amount was a record high of 5.4035 trillion won.
Earlier this January, the company signed its largest contract to date with a European pharmaceutical company worth 2.0747 trillion won, reaching a cumulative order amount of $17.8 billion (25 trillion won). In just the first quarter of this year, it achieved about 40% of last year's total orders. With this additional contract win, the company has already surpassed more than half of last year's total.